Lacosamida Stada

Lacosamide, the active ingredient in Lacosamida Stada, is an anticonvulsant presented as an oral tablet for oral use. It is employed in the treatment of partial‑onset seizures and as adjunctive therapy in epilepsy, helping to stabilize neuronal activity in patients with refractory seizures.

GNH USA supplies Lacosamida Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets through a robust distribution network.

Lacosamide is an anticonvulsant indicated for seizure disorders.

Partial‑onset seizures: used as adjunctive therapy to reduce seizure frequency. Focal epilepsy: improves overall seizure control when combined with other antiepileptic drugs. Adjunctive therapy in epilepsy: contributes to seizure management in patients not controlled by monotherapy.

Lacosamide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Blurred vision - Diplopia

Serious or Rare Side Effects: - Cardiac conduction abnormalities (e.g., PR‑interval prolongation) - Suicidal thoughts or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Hypersensitivity reactions including anaphylaxis - Hepatic enzyme elevations

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

Renal function: assess before initiating therapy. Hepatic function: monitor liver enzymes during treatment. Cardiac conduction: ECG monitoring for PR‑interval prolongation. Concomitant CNS depressants: use with caution. Pregnancy and lactation: risk unknown; weigh benefits versus risks. Store at ambient temperature: keep in original container, protect from moisture and light.

Lacosamide can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide levels. - Class III antiarrhythmics (e.g., amiodarone): may increase lacosamide exposure. - Other sodium‑channel blockers (e.g., lamotrigine): may increase central nervous system adverse effects.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may have reduced efficacy. - Serotonergic agents: monitor for serotonin syndrome. - Alcohol: may enhance dizziness and sedation.